Summary of patient characteristics
| Patient characteristics . | Randomized and treated patients . | . | Fully supplemented patients . | . | ||||
|---|---|---|---|---|---|---|---|---|
| . | Pemetrexed + cisplatin (n = 226) . | Cisplatin (n = 222) . | Pemetrexed + cisplatin (n = 168) . | Cisplatin (n = 163) . | ||||
| Age (y) | ||||||||
| Median (range) | 61 (29-85) | 60 (19-84) | 60 (29-85) | 60 (19-82) | ||||
| Gender (%) | ||||||||
| Male | 184 (81.4) | 181 (81.5) | 136 (81.0) | 134 (82.2) | ||||
| Female | 42 (18.6) | 41 (18.5) | 32 (19.0) | 29 (17.8) | ||||
| Origin (%) | ||||||||
| Caucasian | 204 (90.3) | 206 (92.8) | 150 (89.3) | 153 (93.9) | ||||
| Hispanic | 11 (4.9) | 12 (5.4) | 10 (6.0) | 7 (4.3) | ||||
| Asian | 10 (4.4) | 4 (1.9) | 7 (4.2) | 3 (1.8) | ||||
| African descent | 1 (0.4) | 0 | 1 (0.6) | 0 | ||||
| Stage at entry (%) | ||||||||
| I | 16 (7.1) | 14 (6.3) | 15 (8.9) | 12 (7.4) | ||||
| II | 35 (15.6) | 33 (15.0) | 27 (16.2) | 27 (16.8) | ||||
| III | 73 (32.4) | 68 (30.6) | 51 (30.5) | 49 (30.4) | ||||
| IV | 101 (44.9) | 105 (47.2) | 74 (44.3) | 73 (45.3) | ||||
| Unspecified | 1 (0.4) | 2 (0.9) | 1 (0.6) | 2 (1.2) | ||||
| Diagnosis/histology* (%) | ||||||||
| Epithelial | 154 (68.1) | 152 (68.5) | 117 (69.6) | 113 (69.3) | ||||
| Mixed | 37 (16.4) | 36 (16.2) | 25 (14.9) | 25 (15.3) | ||||
| Sarcomatoid | 18 (8.0) | 25 (11.3) | 14 (8.3) | 17 (10.4) | ||||
| Other | 17 (7.5) | 9 (4.1) | 12 (7.1) | 8 (4.9) | ||||
| Baseline Karnofsky Performance Scale (%) | ||||||||
| 70-80 | 109 (48.2) | 97 (43.7) | 83 (49.4) | 69 (42.3) | ||||
| 90-100 | 117 (51.8) | 125 (56.3) | 85 (50.6) | 94 (57.7) | ||||
| Patient characteristics . | Randomized and treated patients . | . | Fully supplemented patients . | . | ||||
|---|---|---|---|---|---|---|---|---|
| . | Pemetrexed + cisplatin (n = 226) . | Cisplatin (n = 222) . | Pemetrexed + cisplatin (n = 168) . | Cisplatin (n = 163) . | ||||
| Age (y) | ||||||||
| Median (range) | 61 (29-85) | 60 (19-84) | 60 (29-85) | 60 (19-82) | ||||
| Gender (%) | ||||||||
| Male | 184 (81.4) | 181 (81.5) | 136 (81.0) | 134 (82.2) | ||||
| Female | 42 (18.6) | 41 (18.5) | 32 (19.0) | 29 (17.8) | ||||
| Origin (%) | ||||||||
| Caucasian | 204 (90.3) | 206 (92.8) | 150 (89.3) | 153 (93.9) | ||||
| Hispanic | 11 (4.9) | 12 (5.4) | 10 (6.0) | 7 (4.3) | ||||
| Asian | 10 (4.4) | 4 (1.9) | 7 (4.2) | 3 (1.8) | ||||
| African descent | 1 (0.4) | 0 | 1 (0.6) | 0 | ||||
| Stage at entry (%) | ||||||||
| I | 16 (7.1) | 14 (6.3) | 15 (8.9) | 12 (7.4) | ||||
| II | 35 (15.6) | 33 (15.0) | 27 (16.2) | 27 (16.8) | ||||
| III | 73 (32.4) | 68 (30.6) | 51 (30.5) | 49 (30.4) | ||||
| IV | 101 (44.9) | 105 (47.2) | 74 (44.3) | 73 (45.3) | ||||
| Unspecified | 1 (0.4) | 2 (0.9) | 1 (0.6) | 2 (1.2) | ||||
| Diagnosis/histology* (%) | ||||||||
| Epithelial | 154 (68.1) | 152 (68.5) | 117 (69.6) | 113 (69.3) | ||||
| Mixed | 37 (16.4) | 36 (16.2) | 25 (14.9) | 25 (15.3) | ||||
| Sarcomatoid | 18 (8.0) | 25 (11.3) | 14 (8.3) | 17 (10.4) | ||||
| Other | 17 (7.5) | 9 (4.1) | 12 (7.1) | 8 (4.9) | ||||
| Baseline Karnofsky Performance Scale (%) | ||||||||
| 70-80 | 109 (48.2) | 97 (43.7) | 83 (49.4) | 69 (42.3) | ||||
| 90-100 | 117 (51.8) | 125 (56.3) | 85 (50.6) | 94 (57.7) | ||||
Only 67% of the patients had the histologic diagnosis of malignant mesothelioma confirmed by independent review. After independent review epithelial, mixed, and sarcomatoid were the only subtypes; there were no “other.”